Long-term outcomes of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors

Long-term outcomes of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors - EUS-RFA for Pancreatic NET Long-term Outcomes Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061423

Enrollment

Registered

2026-04-30

Start date

2027-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic neuroendocrine tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who participated in the multicenter prospective study titled (Evaluation of the efficacy and safety of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine neoplasms). Patients from whom written informed consent for participation in this study can be obtained based on their own free will.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Relapse-free survival (RFS) *The primary endpoint will be assessed only in patients who achieved curative treatment (complete ablation), as defined in the preceding study.	—

Secondary

Measure	Time frame
Overall survival (OS), progression-free survival (PFS), incidence and worsening of diabetes mellitus, late procedure-related adverse events, and treatment strategies for recurrent or non-curative cases *Secondary endpoints will be assessed in all patients, including those with non-curative treatment (incomplete ablation), as defined in the preceding study.	—

Countries

Japan

Contacts

Public ContactYuki Fujii

Okayama university hospital Gastroenterology

pmug1j9r@okayama-u.ac.jp086-235-7219

Outcome results